Syneos Health (NASDAQ:SYNH) Issues FY20 Earnings Guidance

Syneos Health (NASDAQ:SYNH) issued an update on its FY20 earnings guidance on Wednesday morning. The company provided EPS guidance of $3.58-3.78 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.59. The company issued revenue guidance of $4.88-5.00 billion, compared to the consensus revenue estimate of $4.93 billion.Syneos Health also updated its FY 2020
After-Hours guidance to 3.58-3.78 EPS.

NASDAQ SYNH traded up $0.45 during trading hours on Thursday, hitting $62.95. The company’s stock had a trading volume of 12,125 shares, compared to its average volume of 407,380. Syneos Health has a 12 month low of $36.72 and a 12 month high of $64.72. The company’s 50 day simple moving average is $57.68 and its two-hundred day simple moving average is $53.16. The company has a market cap of $6.61 billion, a P/E ratio of 24.03, a price-to-earnings-growth ratio of 1.79 and a beta of 1.52. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.03 and a quick ratio of 1.03.

Syneos Health (NASDAQ:SYNH) last released its quarterly earnings data on Thursday, October 31st. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.82 by $0.05. The company had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.18 billion. Syneos Health had a return on equity of 10.13% and a net margin of 1.86%. Syneos Health’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period last year, the company earned $0.75 EPS. As a group, research analysts predict that Syneos Health will post 2.81 earnings per share for the current fiscal year.

A number of equities research analysts have issued reports on SYNH shares. Jefferies Financial Group boosted their price target on Syneos Health from $62.00 to $65.00 and gave the company a buy rating in a research note on Monday, September 23rd. Citigroup started coverage on Syneos Health in a research note on Monday, January 6th. They set a buy rating and a $75.00 price target for the company. KeyCorp boosted their price target on Syneos Health from $65.00 to $71.00 and gave the company an overweight rating in a research note on Thursday. ValuEngine upgraded Syneos Health from a sell rating to a hold rating in a research note on Tuesday. Finally, Robert W. Baird boosted their price target on Syneos Health from $62.00 to $74.00 and gave the company an outperform rating in a research note on Thursday. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $63.44.

Syneos Health Company Profile

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Further Reading: What is a dividend reinvestment plan?

Earnings History and Estimates for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with's FREE daily email newsletter.